BLU:CA:TSX-BELLUS Health Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 4.18

Change

-0.02 (-0.48)%

Market Cap

CAD 0.33B

Volume

0.06M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

-0.36 (-2.63%)

CAD1.76B N/A N/A
TRIL:CA Trillium Therapeutics Inc

-0.63 (-5.76%)

CAD1.14B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
APS:CA Aptose Biosciences Inc

-0.17 (-2.94%)

CAD0.51B N/A N/A
MDNA:CA Medicenna Therapeutics Corp

-0.13 (-3.21%)

CAD0.22B 5.40 N/A
RVX:CA Resverlogix Corp

-0.01 (-1.11%)

CAD0.21B 62.86 26.37
IMV:CA IMV Inc

-0.07 (-2.49%)

CAD0.19B -99,999.99 N/A
FRX:CA Fennec Pharmaceuticals Inc

+0.19 (+2.60%)

CAD0.19B 30.20 N/A
ATE:CA Antibe Therapeutics Inc

-0.11 (-2.65%)

CAD0.19B N/A N/A
ONC:CA Oncolytics Biotech Inc

-0.02 (-0.62%)

CAD0.18B N/A N/A

ETFs Containing BLU:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.14% 65% D 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.14% 65% D 57% F
Trailing 12 Months  
Capital Gain -73.21% 6% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.21% 6% F 1% F
Trailing 5 Years  
Capital Gain -38.35% 33% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.35% 33% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain 99.13% 89% B+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.13% 89% B+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 126.77% 26% F 13% F
Risk Adjusted Return 78.20% 95% A 85% B
Market Capitalization 0.33B 79% C+ 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.95 94% A 47% F
Price / Cash Flow Ratio -11.06 37% F 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -26.93% 93% A 15% F
Return on Invested Capital -27.93% 68% D+ 8% F
Return on Assets -16.50% 89% B+ 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 18.48 5% F 3% F
Short Percent N/A N/A N/A N/A N/A
Beta -0.56 100% A+ 100% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector